Literature DB >> 19584741

Using social networks to recruit an HIV vaccine preparedness cohort.

Thomas W Valente1, Jennifer B Zogg, Shawna Christensen, Jean Richardson, Andrea Kovacs, Eva Operskalski.   

Abstract

OBJECTIVES: To evaluate a social network approach to develop an adolescent cohort for HIV vaccine preparedness and investigate characteristics that influence recruitment.
METHODS: We summarize baseline data from a prospective cohort study that included 4 sessions over 6 months. Fifty-nine HIV-infected adolescent and adult patients of a family-based HIV clinic named significant others and indicated willingness to involve them in this study. Sixty-two adolescent and adult significant others not known to be HIV infected were enrolled. Logistic regression was used to estimate factors associated with willingness.
RESULTS: Participants identified 624 social network members including 276 adolescents (44%). Network member's awareness of the index's HIV positivity (P < 0.01) and older age (P = 0.05) affected willingness. Respondents were less willing to invite drug-risk alters (P = 0.006). Adolescents were willing to invite more adolescents than were adults (P < 0.0001). Adolescents younger than 18 years old reported fewer sexual and drug-using risk behaviors than expected.
CONCLUSIONS: HIV-infected patients are willing to recruit their social networks, provided concerns about disclosure of HIV status are addressed. Using social networks to identify and recruit adolescent populations is appropriate and feasible for vaccine preparedness activities, future vaccine trials, and other prevention programs, but procedures are needed to selectively identify and retain high-risk youth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584741      PMCID: PMC2783777          DOI: 10.1097/QAI.0b013e3181acff91

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

1.  Who will enroll? Predicting participation in a phase II AIDS vaccine trial.

Authors:  S D Halpern; D S Metzger; J A Berlin; P A Ubel
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

2.  Recruitment and retention of adolescent participants in HIV research: findings from the REACH (Reaching for Excellence in Adolescent Care and Health) Project.

Authors:  Paulette D Stanford; Dina A Monte; Felecia M Briggs; Patricia M Flynn; Mary Tanney; Jonas H Ellenberg; Kathy L Clingan; Audrey Smith Rogers
Journal:  J Adolesc Health       Date:  2003-03       Impact factor: 5.012

Review 3.  Design and analysis of group-randomized trials: a review of recent methodological developments.

Authors:  David M Murray; Sherri P Varnell; Jonathan L Blitstein
Journal:  Am J Public Health       Date:  2004-03       Impact factor: 9.308

4.  Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.

Authors:  Heather B Jaspan; Coleen K Cunningham; Tim J P Tucker; Peter F Wright; Steve G Self; Rebecca L Sheets; Audrey S Rogers; Linda-Gail Bekker; Craig M Wilson; Ann Duerr; Judith N Wasserheit
Journal:  J Acquir Immune Defic Syndr       Date:  2008-01-01       Impact factor: 3.731

5.  The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection.

Authors:  A Neaigus; S R Friedman; R Curtis; D C Des Jarlais; R T Furst; B Jose; P Mota; B Stepherson; M Sufian; T Ward
Journal:  Soc Sci Med       Date:  1994-01       Impact factor: 4.634

6.  Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City.

Authors:  P Brown-Peterside; M A Chiasson; L Ren; B A Koblin
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

7.  Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study.

Authors:  G R Seage; S E Holte; D Metzger; B A Koblin; M Gross; C Celum; M Marmor; G Woody; K H Mayer; C Stevens; F N Judson; D McKirnan; A Sheon; S Self; S P Buchbinder
Journal:  Am J Epidemiol       Date:  2001-04-01       Impact factor: 4.897

8.  Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials.

Authors:  Anne S Coletti; Patrick Heagerty; Amy R Sheon; Michael Gross; Beryl A Koblin; David S Metzger; George R Seage
Journal:  J Acquir Immune Defic Syndr       Date:  2003-02-01       Impact factor: 3.731

9.  An opportunity for prevention: prevalence, incidence, and sexual risk for HIV among young Asian and Pacific Islander men who have sex with men, San Francisco.

Authors:  Kyung-Hee Choi; Willi McFarland; Torsten B Neilands; Sean Nguyen; Brian Louie; Gina M Secura; Stephanie Behel; Duncan Mackellar; Linda Valleroy
Journal:  Sex Transm Dis       Date:  2004-08       Impact factor: 2.830

10.  Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation.

Authors:  Susan P Buchbinder; Barbara Metch; Sarah E Holte; Susan Scheer; Anne Coletti; Eric Vittinghoff
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

View more
  10 in total

1.  Vaccine research, adolescents and Africa.

Authors:  Amber Abrams; Tamara Kredo
Journal:  Hum Vaccin Immunother       Date:  2012-10-29       Impact factor: 3.452

2.  Overlooked Threats to Respondent Driven Sampling Estimators: Peer Recruitment Reality, Degree Measures, and Random Selection Assumption.

Authors:  Jianghong Li; Thomas W Valente; Hee-Sung Shin; Margaret Weeks; Alexei Zelenev; Gayatri Moothi; Heather Mosher; Robert Heimer; Eduardo Robles; Greg Palmer; Chinekwu Obidoa
Journal:  AIDS Behav       Date:  2018-07

3.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

4.  Barriers to adolescents' participation in HIV biomedical prevention research.

Authors:  Ralph J DiClemente; Monica S Ruiz; Jessica McDermott Sales
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

5.  Enhancing HIV vaccine trial consent preparedness among street drug users.

Authors:  Celia B Fisher
Journal:  J Empir Res Hum Res Ethics       Date:  2010-06       Impact factor: 1.742

6.  Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment.

Authors:  April M Young; Dustin B Stephens; Hanan A Khaleel; Jennifer R Havens
Journal:  Contemp Clin Trials       Date:  2014-12-30       Impact factor: 2.226

7.  Does Whom Patients Sit Next to during Hemodialysis Affect Whether They Request a Living Donation?

Authors:  Avrum Gillespie; Edward L Fink; Heather M Gardiner; Crystal A Gadegbeku; Peter P Reese; Zoran Obradovic
Journal:  Kidney360       Date:  2021-01-15

8.  SRSF3 and SRSF7 modulate 3'UTR length through suppression or activation of proximal polyadenylation sites and regulation of CFIm levels.

Authors:  Oliver Daniel Schwich; Nicole Blümel; Mario Keller; Marius Wegener; Samarth Thonta Setty; Melinda Elaine Brunstein; Ina Poser; Igor Ruiz De Los Mozos; Beatrix Suess; Christian Münch; François McNicoll; Kathi Zarnack; Michaela Müller-McNicoll
Journal:  Genome Biol       Date:  2021-03-11       Impact factor: 13.583

9.  Self-reported depression and social support are associated with egocentric network characteristics of HIV-infected women of color.

Authors:  Lynne C Messer; E Byrd Quinlivan; Adaora Adimora; Katya Roytburd
Journal:  BMC Womens Health       Date:  2020-04-23       Impact factor: 2.809

10.  Protocol for a mixed-methods feasibility study for the surviving opioid overdose with naloxone education and resuscitation (SOONER) randomised control trial.

Authors:  Aaron Orkin; Douglas Campbell; Curtis Handford; Shaun Hopkins; Michelle Klaiman; Pamela Leece; Janet A Parsons; Rita Shahin; Carol Strike; Kevin Thorpe; Kate Sellen; Geoffrey Milos; Amy Wright; Mercy Charles; Ruby Sniderman; Laurie Morrison
Journal:  BMJ Open       Date:  2019-11-12       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.